Dr. Felipe Galvez-Cancino is an immunologist with a long-standing interest in T and myeloid cell biology. He performed his doctoral studies in Chile and the USA at Fundacion Ciencia & Vida and Stanford University. Following his PhD, he pursued postdoctoral training at the Cancer Institute at UCL in London, UK. Since June 2024, Felipe has been a Group Leader and Kidani Fellow at the Centre for Immuno-Oncology at the University of Oxford, where he leads the Immune-Regulation and Immune-Interactions group (IRII).

Felipe’s work has led to key discoveries in the field of vaccination, identifying the role of vaccination-induced tissue-resident memory CD8+ T cells as key players in the immunity against melanoma. Felipe’s latest work has been focused on understanding the mechanisms of action of immunomodulatory agents, particularly depleting antibodies targeting regulatory CD4+ T cells (Tregs) and their interaction with Fc receptors on myeloid cells. These findings have shown that Tregs control the phagocytic capacity of tumour-infiltrating macrophages, axes that could be therapeutically harnessed for drug development. Dr. Galvez-Cancio’s current interest is understanding the phagocytic compartment of liver tumours and sarcomas and developing novel therapies that engage phagocytosis.